Gyre Therapeutics, Inc. reported potential revenues of $400-600 million for liver fibrosis with Hydronidone and expects $100 million for ETUARY® for lung fibrosis on March 10, 2026. They also foresee 20-25% net margins for commercial products and growth opportunities linked to rheumatology diseases.